Acute Lymphoblastic Leukemia Is a Bcl-2 Dependent Disease: Proteomic Profiling and Pre-Clinical Efficacy Of a Selective Bcl-2 Antagonist ABT-199
Konopleva M, Benito JM, Harutyunyan KG, et al.
Key Points:
Expression of Bcl-2 family proteins dysregulated in many cancers and associated with disease progression and resistance to chemotherapy
Proteomic profiling of ALL indicated high levels of expression of Bcl-2, Bax and Bim in patients with t(4;11)translocation
ABT-199 (GDC-0199), a new BH3 mimetic, demonstrated significant anti-tumor activity in preclinical models of ALL expressing high levels of Bcl-2
Implications:
- Targeting Bcl-2 with potent small molecule inhibitors may represent effective treatment strategy in ALL patients with high Bcl-2 expressing tumors
View the original abstract on the ASH website.
